PriceSensitive

MedAdvisor (ASX:MDR) sees CEO transition in line with US growth plans

ASX News, Health Care
ASX:MDR      MCAP $159.8M
05 April 2022 16:50 (AEDT)
MedAdvisor (ASX:MDR) - Outgoing CEO & Managing Director, Robert Read

Source: MedAdvisor

Medical technology company MedAdvisor’s (MDR) CEO and Managing Director, Robert Read, announced his intention to retire from the role.

Mr Read’s departure comes at a time when the company is focused on expanding operations and seizing growth opportunities in the US, where the current CEO is unable to relocate to due to family reasons.

In line with its growth objectives, MedAdvisor’s board determined that a US-based group CEO would best deliver on the next phase of its growth in the US.

“With the largest market and operations now established, it made strategic sense for
MedAdvisor’s Group CEO to be based in the US,” the announcement stated.

Mr Read said it was a difficult decision to retire from the role of CEO and Managing Director.

“I have thoroughly enjoyed the past seven years building MedAdvisor from a small software business in Australia with less than $1 million in revenue, into a global healthcare software provider with operations in four countries and hundreds of staff,” he said.

“With the majority of the business now based in the US, the best path forward is to appoint a US-based Group CEO with deep experience and connections in the US market.”

“Since his appointment as CEO in 2015, Robert has done a tremendous job leading MedAdvisor and to position the company today at the forefront of medications management,” Chair Linda Jenkinson said.

“We completely understand Robert’s desire to remain in Australia and know that he will ensure an orderly and smooth transition of the CEO role,” Ms Jenkinson added.

Company shares were in the grey on market close, trading at 25.5 cents per share.

Related News